Skip to content
DataLookout
Menu

ULTRA-BNCT07928427

Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Local-Regional Recurrence (LRR)
Timeframe: 5 years

Secondary (8)

Acute and Late Toxicities
Overall Survival (OS)
Disease-Free Survival (DFS)
Distant Metastasis-Free Survival (DMFS)
Breast Cancer-Specific Survival (BCSS)
Show 3 moreShow less
EORTC Quality of Life Questionnaire (EORTC-QLQ-C30; version 3)
breast cancer module (QLQ-BR23)
the Quick Disabilities of the Arm, Shoulder and Hand (q-DASH) questionnaire.

Arms and interventions

Ultrafractionated RadiotherapyExperimental

26Gy in 5 fractions to the breast/chest wall with or without regional nodal irradiation. For breast-conserving surgery patients, a simultaneous integrated boost (SIB) of 31Gy in 5 fractions is delivered to the tumor bed.

Moderately Hypofractionated RadiotherapyActive comparator

40Gy in 15 fractions to the breast/chest wall with or without regional nodal irradiation. For breast-conserving surgery patients, a simultaneous integrated boost (SIB) of 48Gy in 15 fractions is delivered to the tumor bed.

Radiation: Ultrafractionated Radiotherapy, Moderately Hypofractionated Radiotherapy

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China